Zoetis Inc. (ZTS) Rating Reiterated by Jefferies Group LLC
Zoetis Inc. (NYSE:ZTS)‘s stock had its “buy” rating restated by Jefferies Group LLC in a report released on Friday. Jefferies Group also issued estimates for Zoetis’ FY2017 earnings at $2.39 EPS, FY2018 earnings at $2.79 EPS, FY2019 earnings at $3.21 EPS, FY2020 earnings at $3.63 EPS and FY2021 earnings at $4.00 EPS.
ZTS has been the subject of a number of other reports. Zacks Investment Research raised shares of Zoetis from a “hold” rating to a “buy” rating and set a $71.00 price objective for the company in a report on Thursday, October 12th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $75.00 price objective on shares of Zoetis in a report on Wednesday, September 6th. BidaskClub lowered shares of Zoetis from a “hold” rating to a “sell” rating in a report on Friday, October 6th. Morgan Stanley increased their price objective on shares of Zoetis from $61.00 to $70.00 and gave the company an “equal weight” rating in a report on Friday, November 3rd. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and set a $62.00 price objective on shares of Zoetis in a report on Monday, August 7th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $67.06.
Shares of Zoetis (NYSE:ZTS) traded down $0.17 on Friday, reaching $69.13. 1,905,724 shares of the company’s stock were exchanged, compared to its average volume of 2,817,385. The company has a debt-to-equity ratio of 2.45, a quick ratio of 1.95 and a current ratio of 2.80. Zoetis has a twelve month low of $48.24 and a twelve month high of $70.48. The stock has a market cap of $33,540.00, a price-to-earnings ratio of 31.89, a P/E/G ratio of 2.03 and a beta of 1.02.
Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, November 2nd. The company reported $0.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.63 by $0.02. Zoetis had a net margin of 18.29% and a return on equity of 62.39%. The business had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.32 billion. During the same period last year, the firm posted $0.52 EPS. The company’s revenue was up 8.5% on a year-over-year basis. equities research analysts expect that Zoetis will post 2.36 EPS for the current year.
A number of institutional investors and hedge funds have recently modified their holdings of ZTS. Northwestern Mutual Wealth Management Co. lifted its position in Zoetis by 16.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock worth $100,000 after buying an additional 230 shares during the last quarter. Harfst & Associates Inc. lifted its position in Zoetis by 16.1% in the second quarter. Harfst & Associates Inc. now owns 1,878 shares of the company’s stock worth $117,000 after buying an additional 260 shares during the last quarter. Almanack Investment Partners LLC. bought a new stake in Zoetis in the second quarter worth $119,000. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its position in Zoetis by 251.9% in the third quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock worth $121,000 after buying an additional 1,360 shares during the last quarter. Finally, Peddock Capital Advisors LLC bought a new stake in Zoetis in the second quarter worth $140,000. Institutional investors own 92.90% of the company’s stock.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Stock Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related stocks with our FREE daily email newsletter.